Novel drug treatments for schizophrenia.
(2026) Prime editing to suppress nonsense mutations.
(2026) Pharmacological targeting of the JAK-STAT pathway: new concepts and emerging indications.
(2026) Promoting prostaglandin signalling for joint repair in osteoarthritis.
(2026) 2025 FDA approvals.
(2026) First antibody-mimetic adnectin nabs an FDA approval.
(2026) Lilly pays US$1.2 billion for Ventyx and its oral anti-inflammatories.
(2026) Redirecting mast cells for antigen-specific cancer immunotherapy.
(2026) Nonopioid analgesic alleviates neuropathic pain.
(2026) Histone methyltransferase inhibition hampers prostate cancer.
(2026) Kinase inhibitors trigger target degradation.
(2026) Boosting CAR T cell efficacy.
(2026) Innate immune receptor agonist for cancer immunotherapy.
(2026) Biopharma dealmaking in 2025.
(2026) 2025 FDA approvals: volume maintained, but value remains below average.
(2026) Hunting for biopharma's innovation sweet spot.
(2026) Strategies for blood-brain barrier rejuvenation and repair.
(2026) Roads and detours for CAR T cell therapy in autoimmune diseases.
(2026) Olfactory receptor activation overcomes obesity.
(2026) The Biomarkers Consortium: 20 years of advancing precision medicine.
(2026) Therapeutic targeting of neuroimmune mechanisms in neurodegeneration.
(2026) TIGIT's immuno-oncology teachings.
(2026) Approvals by the China NMPA in 2025.
(2026) PD1 blockers work best when used in the morning, suggests cancer chronotherapy trial.
(2026) GSK pays US$2 billion for prophylactic food allergen antibody.
(2026) 2025's FDA approvals by regulatory designations.
(2026) Unlocking the potential of disease prevention through regulatory science.
(2026) Antibody-lectin chimeras: new checkpoint inhibitors in the toolbox.
(2026) Two-step screen for CARD9 inhibitors.
(2026) Predicting small-molecule-RNA interactions.
(2026) Lipid flippase inhibitor tackles drug-resistant fungi.
(2026) Spatiotemporal in vivo protein degradation.
(2026) Mapping covalent drug targets.
(2026) Accelerating the drug regulatory process through a federated cloud ecosystem.
(2026) Dose-finding and optimization in drug development for rare diseases.
(2026) The therapeutic potential of orphan adhesion G-protein-coupled receptors.
(2026) Gilead pays US$7.8 billion for Arcellx's next-generation CAR T candidate.
(2026) Clearing cholesterol combats secondary lymphoedema.
(2026) The pancreatic cancer drug market.
(2026) PIP4K2C: an emerging fulcrum for multiple diseases.
(2026) FDA approves dwarfism drug.
(2026) Top companies and drugs by sales in 2025.
(2026) Digital endpoints in clinical trials: building the business case for systematic adoption.
(2026) Author Correction: Novel drug treatments for schizophrenia.
(2026) An allosteric site on cereblon.
(2026) Promoting remyelination.
(2026) Inhibiting advillin in glioblastoma.
(2026) Targeting vascular smooth muscle cells.
(2026) Single-dose sleeping sickness drug set for approval.
(2026) Reshaping Pfizer's drug discovery priorities.
(2026)
(2026) Prime editing to suppress nonsense mutations.
(2026) Pharmacological targeting of the JAK-STAT pathway: new concepts and emerging indications.
(2026) Promoting prostaglandin signalling for joint repair in osteoarthritis.
(2026) 2025 FDA approvals.
(2026) First antibody-mimetic adnectin nabs an FDA approval.
(2026) Lilly pays US$1.2 billion for Ventyx and its oral anti-inflammatories.
(2026) Redirecting mast cells for antigen-specific cancer immunotherapy.
(2026) Nonopioid analgesic alleviates neuropathic pain.
(2026) Histone methyltransferase inhibition hampers prostate cancer.
(2026) Kinase inhibitors trigger target degradation.
(2026) Boosting CAR T cell efficacy.
(2026) Innate immune receptor agonist for cancer immunotherapy.
(2026) Biopharma dealmaking in 2025.
(2026) 2025 FDA approvals: volume maintained, but value remains below average.
(2026) Hunting for biopharma's innovation sweet spot.
(2026) Strategies for blood-brain barrier rejuvenation and repair.
(2026) Roads and detours for CAR T cell therapy in autoimmune diseases.
(2026) Olfactory receptor activation overcomes obesity.
(2026) The Biomarkers Consortium: 20 years of advancing precision medicine.
(2026) Therapeutic targeting of neuroimmune mechanisms in neurodegeneration.
(2026) TIGIT's immuno-oncology teachings.
(2026) Approvals by the China NMPA in 2025.
(2026) PD1 blockers work best when used in the morning, suggests cancer chronotherapy trial.
(2026) GSK pays US$2 billion for prophylactic food allergen antibody.
(2026) 2025's FDA approvals by regulatory designations.
(2026) Unlocking the potential of disease prevention through regulatory science.
(2026) Antibody-lectin chimeras: new checkpoint inhibitors in the toolbox.
(2026) Two-step screen for CARD9 inhibitors.
(2026) Predicting small-molecule-RNA interactions.
(2026) Lipid flippase inhibitor tackles drug-resistant fungi.
(2026) Spatiotemporal in vivo protein degradation.
(2026) Mapping covalent drug targets.
(2026) Accelerating the drug regulatory process through a federated cloud ecosystem.
(2026) Dose-finding and optimization in drug development for rare diseases.
(2026) The therapeutic potential of orphan adhesion G-protein-coupled receptors.
(2026) Gilead pays US$7.8 billion for Arcellx's next-generation CAR T candidate.
(2026) Clearing cholesterol combats secondary lymphoedema.
(2026) The pancreatic cancer drug market.
(2026) PIP4K2C: an emerging fulcrum for multiple diseases.
(2026) FDA approves dwarfism drug.
(2026) Top companies and drugs by sales in 2025.
(2026) Digital endpoints in clinical trials: building the business case for systematic adoption.
(2026) Author Correction: Novel drug treatments for schizophrenia.
(2026) An allosteric site on cereblon.
(2026) Promoting remyelination.
(2026) Inhibiting advillin in glioblastoma.
(2026) Targeting vascular smooth muscle cells.
(2026) Single-dose sleeping sickness drug set for approval.
(2026) Reshaping Pfizer's drug discovery priorities.
(2026)
